DiaSorin has identified that lots 136344, 136344A, 136344B, 136344C, 136520, 136520A, 136520B, 136520C, 136604, 136703, 136703A, 136703B, 136703C
136775of LIAISON HSV-2 Type Specific IgG assay may produce increased equivocal and/or false positive results.
Source facts
Action
DiaSorin issued a DIASORIN CUSTOMER NOTIFICATION LETTER to its consignees on 12/13/2023 via email. The notice explained the issue, risk to health, and requested the disposal of all affected inventory. The firm will be providing replacement kits.
Initiated
2023-12-13
Root cause
Under Investigation by firm
Distribution
Worldwide distribution - US Nationwide and the country of Canada.
Recall number
Z-0815-2024
Recall status
Open, Classified
CDRH record ID
205347
FDA classified
2024-01-25
Recall event number
93741
Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.
Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.